VTGN vs. YMAB, VIGL, ATXS, FULC, ABEO, INBX, ADCT, CTMX, ALDX, and BNTC
Should you be buying VistaGen Therapeutics stock or one of its competitors? The main competitors of VistaGen Therapeutics include Y-mAbs Therapeutics (YMAB), Vigil Neuroscience (VIGL), Astria Therapeutics (ATXS), Fulcrum Therapeutics (FULC), Abeona Therapeutics (ABEO), Inhibrx Biosciences (INBX), ADC Therapeutics (ADCT), CytomX Therapeutics (CTMX), Aldeyra Therapeutics (ALDX), and Benitec Biopharma (BNTC). These companies are all part of the "pharmaceutical products" industry.
VistaGen Therapeutics vs. Its Competitors
VistaGen Therapeutics (NASDAQ:VTGN) and Y-mAbs Therapeutics (NASDAQ:YMAB) are both small-cap medical companies, but which is the superior business? We will compare the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, media sentiment, profitability, earnings and valuation.
Y-mAbs Therapeutics has a consensus target price of $9.62, indicating a potential upside of 12.54%. Given Y-mAbs Therapeutics' higher possible upside, analysts plainly believe Y-mAbs Therapeutics is more favorable than VistaGen Therapeutics.
VistaGen Therapeutics has a beta of 0.55, suggesting that its share price is 45% less volatile than the S&P 500. Comparatively, Y-mAbs Therapeutics has a beta of 0.53, suggesting that its share price is 47% less volatile than the S&P 500.
78.4% of VistaGen Therapeutics shares are owned by institutional investors. Comparatively, 70.9% of Y-mAbs Therapeutics shares are owned by institutional investors. 2.9% of VistaGen Therapeutics shares are owned by insiders. Comparatively, 19.7% of Y-mAbs Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Y-mAbs Therapeutics has a net margin of -26.03% compared to VistaGen Therapeutics' net margin of -6,777.08%. Y-mAbs Therapeutics' return on equity of -24.60% beat VistaGen Therapeutics' return on equity.
Y-mAbs Therapeutics has higher revenue and earnings than VistaGen Therapeutics. Y-mAbs Therapeutics is trading at a lower price-to-earnings ratio than VistaGen Therapeutics, indicating that it is currently the more affordable of the two stocks.
In the previous week, Y-mAbs Therapeutics had 2 more articles in the media than VistaGen Therapeutics. MarketBeat recorded 3 mentions for Y-mAbs Therapeutics and 1 mentions for VistaGen Therapeutics. VistaGen Therapeutics' average media sentiment score of 1.88 beat Y-mAbs Therapeutics' score of 1.17 indicating that VistaGen Therapeutics is being referred to more favorably in the media.
Summary
Y-mAbs Therapeutics beats VistaGen Therapeutics on 9 of the 16 factors compared between the two stocks.
Get VistaGen Therapeutics News Delivered to You Automatically
Sign up to receive the latest news and ratings for VTGN and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding VTGN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
VistaGen Therapeutics Competitors List
Related Companies and Tools
This page (NASDAQ:VTGN) was last updated on 9/1/2025 by MarketBeat.com Staff
Free VTGN Stock Alerts